Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1944-446X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers ; volume:36 ; number:1 ; day:10 ; month:5 ; year:2017 ; pages:1-2 ; date:12.2017
Chinese journal of cancer ; 36, Heft 1 (10.5.2017), 1-2, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Altundag, Kadri
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40880-017-0208-5
- URN
-
urn:nbn:de:1111-201705204939
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Altundag, Kadri
- SpringerLink (Online service)
Other Objects (12)
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer